U.S. markets closed
  • S&P 500

    4,122.47
    -17.59 (-0.42%)
     
  • Dow 30

    32,774.41
    -58.13 (-0.18%)
     
  • Nasdaq

    12,493.93
    -150.53 (-1.19%)
     
  • Russell 2000

    1,912.89
    -28.31 (-1.46%)
     
  • Crude Oil

    90.45
    -0.05 (-0.06%)
     
  • Gold

    1,810.80
    -1.50 (-0.08%)
     
  • Silver

    20.49
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0216
    +0.0021 (+0.20%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • GBP/USD

    1.2076
    -0.0006 (-0.05%)
     
  • USD/JPY

    135.0830
    +0.1100 (+0.08%)
     
  • BTC-USD

    23,178.25
    -651.48 (-2.73%)
     
  • CMC Crypto 200

    537.23
    -20.12 (-3.61%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,999.96
    -249.28 (-0.88%)
     

Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc.

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming conferences:

  • The Alzheimer’s Association International Conference (AAIC), in San Diego and virtually, from Sunday, July 31, to Thursday, August 4, 2022

    • Acumen scientists will present a poster, “Preparation and qualification of soluble amyloid beta oligomers for use in bioanalytic assays supporting Alzheimer’s disease therapeutics,” (P4-178) on August 3

  • The BTIG Biotech Conference, in New York and virtually, on Monday, August 8, 2022 at 2:00 pm ET

    • Dr. Eric Siemers, Chief Medical Officer, will be participating in an AD panel: “The Next Generation of Anti-Amyloid and Anti-Tau Targeting Therapeutics for Alzheimer's Disease”

About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, headquartered in Charlottesville, Va. with clinical operations based in Carmel, Ind., is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on toxic soluble AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AβOs in a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Contacts:

Media:
AcumenPR@westwicke.com

Investors:
investors@acumenpharm.com